No Detail Found!

Clinical Eficacy and Safety of transarterial chemoembolization Combined with Targeted Therapy for primary hepatocellular carcinoma

Author(s)
Xiao Wang Department of Infectious Diseases, Renmin Hospital, Hubei University of Medicine, Shiyan 442000, Hubei, P.R. China.
Dan Zhang Department of Infectious Diseases, Renmin Hospital, Hubei University of Medicine, Shiyan 442000, Hubei, P.R. China.
Kang Li Department of Nursing, National Medicine Dongfeng General Hospital, Hubei University of Medicine, Shiyan 442000, Hubei, P.R. China.
Peng Guo Department of Infectious Diseases, Renmin Hospital, Hubei University of Medicine, Shiyan 442000, Hubei, P.R. China.
Zhi-xiong Lei Department of Infectious Diseases, Renmin Hospital, Hubei University of Medicine, Shiyan 442000, Hubei, P.R. China.
Abstract
Objective: To explore the clinical eficacy and safety of transarterial chemoembolization (TACE) combined with targeted therapy for primary hepatocellular carcinoma (PHC). Methods: This was a retrospective study. Retrospective selection of 150 PHC patients admitted to the Renmin Hospital, Hubei University of Medicine January 2019 and June 2021 were included. The patients were divided into the control group and the experimental group according to their treatment regimens. The control group received TACE treatment, while the experimental group received TACE combined with targeted therapy. We analyze the relevant data of two groups of patients and evaluate the clinical eficacy and safety of TACE combined with targeted therapy. Results: The tumor remission rate and control rate in the control group were 41.89% and 75.68%, respectively, while those in the experimental group were 77.63% and 90.79%, with statistically significant diferences (p<0.05). The 1-year and 3-year recurrence rates in the control group were 52.71% and 98.65%, respectively, while those in the experimental group were 39.47% and 61.84%, with statistically significant diferences (p<0.05). After treatment, the AFP, VEGF, ALT, and AST in the experimental group were significantly reduced compared to the control group (p<0.05). During the treatment period, the incidence and severity of nausea, vomiting, and fever in the experimental group were significantly lower than those in the control group (p<0.05). Conclusion: The clinical eficacy of TACE combined with targeted therapy for PHC is superior to that of TACE alone, with improved disease control rate, improved long-term survival rate, and good safety.
Publication Details
Page(s) 1663-1668
Published Journal: Pakistan Journal of Medical Sciences, Volume: 40, Issue: 8, Year: 2024

Request the full text from PASTIC

Keywords
Safety, TACE, Targeted therapy, clinical eficacy, PHC
References
Hassan S,Shah H,Shawana S H .2020 .Dysregulated epidermal growth factor and tumor growth factor-beta receptor signaling through GFAP-ACTA2 protein interaction in liver fibrosis. Pak J Med Sci, 10(4) : 782-787.
Raoul J,Forner A,Bolondi L,Cheung TT,Kloeckner R .2018 .Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev, 11 : 28-36.
Grégory J,Créquit P,Vilgrain V,Ronot M,Boutron I. .2020 .Results of trials assessing transarterial chemoembolization for treating hepatocellular carcinoma are critically underreported. Eur Radiol, 10(10) : 5633-5640.
Liu Z,Lin Y,Zhang J,Zhang Y,Li Y,Liu Z .2019 .Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma. J Exp Clin Cancer Res, 10(1) : 447.
Sadeghi S,Bejjani A,Finn RS .2019 .Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma. Surg Oncol Clin N Am, 06(4) : 695-715.
Feng F,Jiang Q,Jia H,Sun H,Chai Y,Li X .2018 .Which is the best combination of TACE and Sorafenib for advanced hepatocellular carcinoma treatment? A systematic review and network metaanalysis. Pharmacol Res, 06 : 89-101.
Zhou J,Sun H,Wang Z,Cong W,Wang J,Zeng M .2020 .Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer, 10(6) : 682-720.
Shao L,Wang X,Yu Y,Xie J .2021 .Comparative analysis of the efficacy and accuracy of magnetic resonance imaging (MRI) and contrast-enhanced CT for residual and new lesions after transcatheter arterial chemoembolization (TACE) in patients with primary liver cancer. Transl Cancer Res, 10(8) : 3739-3747.
Wong JK,Lim HJ,Tam VC,Burak KW,Dawson LA,Chaudhury P .2023 .Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada. Cancer Treat Rev, 10 : 102526.
Tang J,Sui C,Wang D,Lu X,Luo G,Zhao Q .2020 .Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma. Theranostics, 10(12) : 5384-5397.
Cao W,Liu J,Wang L,Li M,Verstegen MMA,Yin Y .2019 .Modeling liver cancer and therapy responsiveness using organoids derived from primary mouse liver tumors. Carcinogenesis, 10(1) : 145-154.
Cheng A,Hsu C,Chan SL,Choo S,Kudo M. .2019 .Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol, 09(2) : 307-319.
Celsa C,Cabibbo G,Pagano D,Marco VD,Cammà C .2020 .Gruttadauria S. Sicily Network for Liver Cancer: A Multidisciplinary Network Model for the Management of Primary Liver Tumors. J Laparoendosc Adv Surg Tech A, 10(10) : 1048-1053.
Yang G,Xiong Y,Sun J,Wang G,Li W,Tang T .2020 .The efficacy of microwave ablation versus liver resection in the treatment of hepatocellular carcinoma and liver metastases: A systematic review and meta-analysis. Int J Surg, 03 : 85-93.
Anwanwan D,Singh SK,Singh S,Saikam V,Singh R. .2019 .1):188314. Biochim Biophys Acta Rev Cancer, 10 : .
Kim KW .2019 .Evolution of Transarterial Chemoembolization for the Treatment of Liver Cancer. Radiology, 10(3) : 704-706.
Meyer T,Fox R,Ma YT,Ross PJ,James MW,Sturgess R .2017 .Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol, 1253(17) : 30156-5.
Kimura Y,Kaneko R,Yano Y,Kamada K,Ikehara T,Nagai H,Asian Pac J Cancer Prev H .2020 .The Prognosis of Hepatocellular Carcinoma Treated with Sorafenib in Combination with TACE. , 21(6) : 1797-1805.
Kudo M,Ueshima K,Ikeda M,Torimura T,Tanabe N,Aikata H .2020 .Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. -318934, 10(8) : 1492-1501.
Varghese J,Kedarisetty C,Venkataraman J,Srinivasan V,Deepashree T,Uthappa M .2017 .Combination of TACE and Sorafenib Improves Outcomes in BCLC Stages B/C of Hepatocellular Carcinoma: A Single Centre Experience. , 10(2) : 247-254.
0

Citations

0

Downloads

73

Views